IE Krop

A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC)

M. Beeram, H. A. Burris, Shanu Modi et al. · Journal of Clinical Oncology · 2008 · 48 citations

Breast Oncology, Immunology, Pharmacotherapy +23

Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors

IE Krop, Michele Kosh, Ivy Fearen et al. · Journal of Clinical Oncology · 2006 · 39 citations

Breast Oncology, Immunology, Pathology +20

Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)

SM Tolaney, WT Barry, CT Dang et al. · Cancer Research · 2013 · 36 citations

Dfs Events, Breast Oncology, Overall Survival +12

A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients (pts) with advanced HER2+ breast cancer (BC)

Scott N. Holden, M. Beeram, IE Krop et al. · Journal of Clinical Oncology · 2008 · 32 citations

Breast Oncology, T. T-dm1, Immunology +21

259P Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer

Ming‐Lin Tsai, Heon Han, A.J. Montero et al. · Annals of Oncology · 2021 · 29 citations

Breast Oncology, Medicine, Pathology +5